Journal article
parC Variants in Mycoplasma genitalium: Trends over Time and Association with Moxifloxacin Failure
GL Murray, K Bodiyabadu, LA Vodstrcil, DA Machalek, J Danielewski, EL Plummer, SM Garland, DM Whiley, EL Sweeney, CS Bradshaw
Antimicrobial Agents and Chemotherapy | AMER SOC MICROBIOLOGY | Published : 2022
DOI: 10.1128/aac.00278-22
Abstract
Prevalence, trends, and treatment outcome estimates were generated for parC variants in macrolide-resistant Mycoplasma genitalium. Among 539 cases, the most common amino acid change was S83I, which increased from 13% in 2012 to 2013, to 23% in 2019 to 2020 (Ptrend = 0.046). From 381 moxifloxacin treatments, failure occurred in 58.7% (95% confidence interval [CI], 46.7 to 69.9) of cases with S83I. Other changes affecting S83 or D87 were uncommon and minor contributors to failure. The absence of S83I was highly predictive of moxifloxacin cure (96.4%; 95% CI, 93.7 to 98.2), highlighting diagnostic potential.
Related Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work is supported by the Australian Research Council Research Hub to Combat Antimicrobial Resistance (project ID IH190100021 to G.L.M., C.S.B., and D.M.W.) and National Health and Medical Research Council Investigator Grant APP1197951 (to S.M.G.).